Ishara Investments LP Invests $1.05 Million in NewAmsterdam Pharma Company N.V. $NAMS

Ishara Investments LP bought a new position in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 30,000 shares of the company’s stock, valued at approximately $1,052,000. NewAmsterdam Pharma makes up approximately 1.2% of Ishara Investments LP’s investment portfolio, making the stock its 28th largest holding.

A number of other institutional investors have also made changes to their positions in NAMS. Wells Fargo & Company MN lifted its stake in shares of NewAmsterdam Pharma by 50.0% in the fourth quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock worth $32,000 after acquiring an additional 300 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of NewAmsterdam Pharma by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 102,395 shares of the company’s stock worth $3,590,000 after acquiring an additional 437 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of NewAmsterdam Pharma by 5.3% in the second quarter. The Manufacturers Life Insurance Company now owns 10,868 shares of the company’s stock worth $197,000 after acquiring an additional 544 shares in the last quarter. Farther Finance Advisors LLC lifted its stake in shares of NewAmsterdam Pharma by 4,425.0% in the fourth quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock worth $25,000 after acquiring an additional 708 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of NewAmsterdam Pharma by 26.6% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,510 shares of the company’s stock worth $193,000 after acquiring an additional 1,156 shares in the last quarter. 89.89% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

NAMS has been the topic of several recent analyst reports. Needham & Company LLC boosted their price target on NewAmsterdam Pharma from $46.00 to $48.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Wall Street Zen upgraded NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Guggenheim upped their price target on shares of NewAmsterdam Pharma from $41.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, February 19th. Truist Financial initiated coverage on shares of NewAmsterdam Pharma in a report on Wednesday, March 18th. They issued a “buy” rating and a $57.00 price target on the stock. Finally, HC Wainwright raised shares of NewAmsterdam Pharma to a “strong-buy” rating in a report on Thursday, February 19th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $48.60.

Insider Transactions at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 65,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $35.69, for a total transaction of $2,319,850.00. Following the sale, the chief accounting officer owned 24,353 shares in the company, valued at $869,158.57. This represents a 72.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 12.74% of the stock is owned by insiders.

NewAmsterdam Pharma Stock Down 0.1%

Shares of NASDAQ NAMS opened at $30.15 on Thursday. The stock’s 50 day moving average price is $33.26 and its two-hundred day moving average price is $33.42. NewAmsterdam Pharma Company N.V. has a 52-week low of $17.63 and a 52-week high of $42.21. The stock has a market capitalization of $3.52 billion, a P/E ratio of -16.84 and a beta of 0.07.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings data on Tuesday, March 31st. The company reported ($0.40) earnings per share (EPS) for the quarter. NewAmsterdam Pharma had a negative net margin of 943.23% and a negative return on equity of 26.49%. The firm had revenue of $3.04 million for the quarter. On average, analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.78 EPS for the current year.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.